- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient-Centered Oncology Care 2015: When Precision Medicine Meets Regulation
Before "value" became a cancer care buzzword, The American Journal of Managed Care was the first to create a conference where stakeholders discussed how to deliver the best care possible-and figure out how to pay for it. The fourth installment of Patient-Centered Oncology Care on November 19-20, 2015, in Baltimore, Maryland, will address the regulation of molecular diagnostics and ongoing efforts at payment reform.
FOR IMMEDIATE RELEASEJuly 27, 2015
PLAINSBORO, N.J.—The promise of precision medicine puts effective cancer care within reach of more patients than ever, but the cost of that care presents hurdles that more will face as the nation ages and oncology drug prices escalate.
How stakeholders—payers, providers, policymakers, patient advocates and leaders from the pharmaceutical industry—address these challenges is the purpose of the 2015 session of Patient Centered Oncology Care, to be held November 19-20 in Baltimore, Maryland, at the Marriott Waterfront. A full agenda and registration can be found here.
Precision medicine will be high on the agenda, including the regulation of diagnostic testing, reimbursement challenges, and how President Obama’s initiative will affect clinical practice. Speakers and a panel discussion on immuno-oncology, as well as updates on new payment models and the influence of accountable care organizations will give attendees a cross section of all the elements affecting cancer care today.
“Today’s practicing oncologist must follow not only scientific developments but also the changes in healthcare management, reimbursement, and regulation,” said Brian Haug, president of The American Journal of Managed Care and the conference host. “It’s rare to hear at one meeting how all those pieces fit together, but each year we raise the bar with better information from the most important leaders in cancer care.”
Discussions at Patient-Centered Oncology Care 2015 include:
- The impact of FDA regulation on molecular diagnostic testing in oncology, featuring Bruce Quinn, MD, PhD, of Foley Hoag, Michael Kolodziej, MD, of Aetna, and Scott Gottlieb, MD, of the American Enterprise Institute.
- Reimbursement challenges in oncology featuring Daniel Klelin of the PAN Foundation, Syed Yousuf Zafar, MD, of the Duke Cancer Institute, Peter Bach, MD, Memorial Sloan-Kettering, and John Fox, MD, MHA, of Priority Health.
- An examination of the the conflict between competing mandates for "personalized medicine" and "population management" featuring Burton VanderLaan, MD, of Priority Health, Debra Patt, MD, MPH, of Texas Oncology, and Joseph C. Alvarnas, MD, of City of Hope, who is also editor in chief of AJMC's Evidence-Based Oncology.
About the Journals
The American Journal of Managed Care celebrates its 20th year in 2015 as the leading peer-reviewed journal dedicated to issues in managed care. Other titles in the franchise include The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care, and The American Journal of Accountable Care, which publishes research and commentary on new healthcare delivery models facilitated by the 2010 Affordable Care Act. AJMC’s news publications, the Evidence-Based series, bring together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
CONTACT: Nicole Beagin (609) 716-7777 x 131
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
